Loading next page...
1 Page
/lp/springer_journal/multiple-drugs-ZJ0z2ZUKR0
- Publisher
- Springer Journals
- Copyright
- Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
- Subject
- Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
- ISSN
- 0114-9954
- eISSN
- 1179-2051
- D.O.I.
- 10.1007/s40278-018-46904-6
- Publisher site
- See Article on Publisher Site
Abstract
Reactions 1704, p261 - 2 Jun 2018 O S Various toxicities: 10 case reports A case report originating from the centre of evaluation and information on pharmacodependence-addictovigilance of Paris described ten patients (seven men and three women), aged 25 84 years, who developed dependence to mephenesin; most of these patients were abusing mephenesin at an overdose. Four of ten patients also developed dependence to alprazolam, zolpidem, promethazine, doxylamine, codeine or bromazepam. Three of ten patients developed sleep disorder, anxiety, agitation, tremor or irritability following the withdrawal of mephenesin [routes, durations of treatments to reaction onsets and outcomes not stated, not all dosages and indication stated]. The patients had a history of depression, alcoholism, high BP, chronic obstructive pulmonary disease, fractured collarbone, capsulitis, sleep disorder, lumbar pain, childhood maltreatment, discal hernia, arthrosis, scoliosis, eating disorders, medication overuse headache, back pain or physical disability. Additionally, in six of the 10 patients, history was significant for alcoholism, overweight, gambling, illicit drugs use, alcohol abuse or cannabis use. The social history was significant for only tobacco (three patients), only alcohol (one patient) and both alcohol and tobacco (two patients). Seven of the ten patients were also receiving current medications. All the patients received mephenesin and dose was – – 1 144 gram/day for a duration of 3 months 6 years (8 patients). Six of the 10 patients were using mephenesin to seek effect such as sedation, anxiolytic, hypnotic, sensation of well-being, analgesic or anti-craving for alcohol. Thereafter, eight of the 10 patients, met the criteria for diagnostic and statistical manual of mental disorders fifth edition for substance-related and addictive disorders, while in two patients it was unknown for mephenesin. The treatment with mephenesin was discontinued in all the patients. In three of the 10 patients developed sleep disorder (n=1), anxiety, agitation, sleep disorder and tremor (n=1) and anxiety, tremor and irritability (n=1) following the withdrawal of mephenesin. In four the 10 patients multiple drug dependence was noted, of which two patients were also dependent on alprazolam, one patient on zolpidem, promethazine and doxylamine and remaining one patient on codeine and bromazepam. Author comment: "[W]e reported 10 new clinical cases of mephenesin use disorder collected between 2012 and 2017." "Four patients presented multiple drug dependence." Chevallier C, et al. Mephenesin: Is There a Progression in Cases of Substance Use Related Disorders in France?. Journal of Clinical Psychopharmacology 38: 275-277, No. 3, Jun 2018. Available from: URL: http://doi.org/10.1097/ JCP.0000000000000884 - France 803323796 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704
Journal
Reactions Weekly – Springer Journals
Published: Jun 2, 2018
@Phil_Robichaud
@deepthiw
@JoseServera